Semerdzhieva Niya E, Denchev Stefan V, Gospodinova Mariana V
Emergency Department, National Heart Hospital, Sofia, BGR.
Cardiology Department, Medical Center 'Mediva', Sofia, BGR.
Cureus. 2022 May 6;14(5):e24789. doi: 10.7759/cureus.24789. eCollection 2022 May.
Background An interplay of myocardial structural abnormalities and coronary arterial dysfunction underlies the worsening left ventricular compliance. The conventionally used angina drugs have demonstrated a beneficial effect on both angina and coronary flow in cases with microvascular dysfunction and non-obstructive coronary disease. Despite that, vasoactive therapy only partially affects diastolic function in this patient population. Purpose This retrospective study was planned to evaluate the association of myocardial mass, delayed epicardial coronary flow, and vasoactive drugs with parameters of diastolic function in two cohorts with preserved left ventricular function and non-obstructive coronary disease in patients with slow coronary flow phenomenon (SCFP) and patients with the hypertensive disease and left ventricular hypertrophy. Material and methods The epicardial coronary flow was evaluated in 48 patients with unstable angina in the absence of coronary stenosis >50%, by applying the methods of corrected thrombolysis in myocardial infraction frame count (cTFC). The abnormalities in the left ventricular function were assessed by echocardiography using PW-Doppler of the diastolic mitral inflow and tissue Doppler imaging. Twenty-one (43.8%) patients were diagnosed with SCFP, and twelve patients (25%) had slow epicardial coronary flow, hypertensive disease, and ventricular hypertrophy (SF). The remaining 15 (31.3%) were patients with ventricular hypertrophy, hypertension, and non-delayed epicardial coronary flow (NF). Results The patients with SF showed reduced peak early diastolic lateral mitral annular velocity (e') when compared to SCFP (7.1±1.9cm/s vs 8.6±2.1 cm/s, p=0.045) and NF (7.1±1.9 cm/s vs 8.7±1.8 cm/s, p=0.018). A borderline significant difference was observed for the peak early diastolic septal mitral annular velocity (e'S) between the patients with SF and SCFP ( 7.0±1.3 cm/s vs 8.3±2.1 cm/s, p=0.057). The ratio of mitral diastolic inflow velocity to early diastolic velocity of the mitral annulus (E/e') in the SF group was a tendency higher than E/e' of the patients with SCFP (9.8±3.1 vs. 8.2±2.1, p=0.084) and NF (9.8±3.1 vs. 7.8±1.5, p=0.051) .In the group with left ventricular hypertrophy, E/e' >10 was more frequently observed in patients with a marked delay in the epicardial flow (33.1 ± 13.1 frames vs. 25.4 ± 11.8 frames, p=0.011) and higher left ventricular mass (146.9 ± 17.7 g/m2 vs. 126.1 ± 121.5 g/m2, p=0.027). Conclusions Patients with microvascular angina represent a diverse population. The echocardiographic parameters of left ventricular relaxation (e') and end-diastolic pressure (E/e') are abnormally altered in the population with left ventricular hypertrophy compared to SCFP. The delayed epicardial flow further impairs diastolic function in hypertensive patients with hypertrophy and non-obstructive coronary disease.
背景 心肌结构异常与冠状动脉功能障碍的相互作用是左心室顺应性恶化的基础。传统使用的抗心绞痛药物已证明对微血管功能障碍和非阻塞性冠状动脉疾病患者的心绞痛和冠状动脉血流均有有益作用。尽管如此,血管活性治疗仅部分影响该患者群体的舒张功能。目的 本回顾性研究旨在评估心肌质量、延迟的心外膜冠状动脉血流和血管活性药物与两组左心室功能保留且患有冠状动脉血流缓慢现象(SCFP)的非阻塞性冠状动脉疾病患者以及高血压疾病和左心室肥厚患者舒张功能参数之间的关联。材料和方法 通过应用校正心肌梗死溶栓帧数(cTFC)方法,对48例无冠状动脉狭窄>50%的不稳定型心绞痛患者的心外膜冠状动脉血流进行评估。使用舒张期二尖瓣流入PW - 多普勒和组织多普勒成像通过超声心动图评估左心室功能异常。21例(43.8%)患者被诊断为SCFP,12例(25%)患者有心外膜冠状动脉血流缓慢、高血压疾病和心室肥厚(SF)。其余15例(31.3%)为有心室肥厚、高血压且心外膜冠状动脉血流未延迟的患者(NF)。结果 与SCFP(7.1±1.9cm/s对8.6±2.1cm/s,p = 0.045)和NF(7.1±1.9cm/s对8.7±1.8cm/s,p = 0.018)相比,SF患者舒张早期二尖瓣环侧壁峰值速度(e')降低。SF患者与SCFP患者之间舒张早期二尖瓣环间隔峰值速度(e'S)观察到临界显著差异(7.0±1.3cm/s对8.3±2.1cm/s,p = 0.057)。SF组二尖瓣舒张期流入速度与二尖瓣环舒张早期速度之比(E/e')有高于SCFP患者(9.8±3.1对8.2±2.1,p = 0.084)和NF患者(9.8±3.1对7.8±1.5,p = 0.051)的趋势。在左心室肥厚组中,心外膜血流明显延迟(33.1±13.1帧对25.4±11.8帧,p = 0.011)和左心室质量较高(146.9±17.7g/m²对126.1±121.5g/m²,p = 0.027)的患者中更频繁观察到E/e'>10。结论 微血管性心绞痛患者构成一个多样化群体。与SCFP相比,左心室肥厚人群中左心室舒张(e')和舒张末期压力(E/e')的超声心动图参数异常改变。延迟的心外膜血流进一步损害肥厚型高血压和非阻塞性冠状动脉疾病患者的舒张功能。